112 related articles for article (PubMed ID: 9213204)
1. Hemodynamic and autonomic effects of intravenous saterinone in patients with chronic heart failure.
Szabó BM; van Veldhuisen DJ; van Dijk RB; Lahiri A; Mitrovic V; Stolzenburg K; Brouwer J; Lie KI
J Cardiovasc Pharmacol; 1997 May; 29(5):618-23. PubMed ID: 9213204
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics and hemodynamic effects of the phosphodiesterase III inhibitor saterinone in patients with chronic heart failure.
Kieback AG; Iven H; Stolzenburg K; Eichner E; Ruckdeschel W; Baumann G
Int J Cardiol; 2003 Oct; 91(2-3):201-8. PubMed ID: 14559131
[TBL] [Abstract][Full Text] [Related]
3. Saterinone, dobutamine, and sodium nitroprusside: comparison of cardiovascular profiles in patients with congestive heart failure.
Kieback AG; Iven H; Stolzenburg K; Baumann G
J Cardiovasc Pharmacol; 1998 Oct; 32(4):629-36. PubMed ID: 9781932
[TBL] [Abstract][Full Text] [Related]
4. Acute hemodynamic effects of intravenous sildenafil citrate in congestive heart failure: comparison of phosphodiesterase type-3 and -5 inhibition.
Botha P; Parry G; Dark JH; Macgowan GA
J Heart Lung Transplant; 2009 Jul; 28(7):676-82. PubMed ID: 19560695
[TBL] [Abstract][Full Text] [Related]
5. Multicenter, double-blind study of intravenous milrinone for patients with acute heart failure in Japan. Japan Intravenous Milrinone Investigators.
Seino Y; Momomura S; Takano T; Hayakawa H; Katoh K
Crit Care Med; 1996 Sep; 24(9):1490-7. PubMed ID: 8797620
[TBL] [Abstract][Full Text] [Related]
6. Hemodynamic and neuroendocrine response to acute administration of the phosphodiesterase inhibitor BM14.478 in patients with congestive heart failure.
Rauch B; Zimmermann R; Kapp M; Haass M; Von Molitor S; Smolarz A; Neumann FJ; Kübler W; Dietz R; Tillmanns H
Clin Cardiol; 1991 May; 14(5):386-95. PubMed ID: 2049889
[TBL] [Abstract][Full Text] [Related]
7. Hemodynamic and neurohumoral responses to intravenous nicorandil in congestive heart failure in humans.
Giles TD; Pina IL; Quiroz AC; Roffidal L; Zaleski R; Porter RS; Karalis DG; Mohrland JS; Wolf DL; Hearron AE
J Cardiovasc Pharmacol; 1992 Oct; 20(4):572-8. PubMed ID: 1280713
[TBL] [Abstract][Full Text] [Related]
8. Dissociation between ACE activity and autonomic response to ACE inhibition in patients with heart failure.
Binkley PF; Nunziata E; Haas GJ; Starling RC; Leier CV; Cody RJ
Am Heart J; 2000 Jul; 140(1):34-42. PubMed ID: 10874261
[TBL] [Abstract][Full Text] [Related]
9. Phosphodiesterase III inhibition or adrenoreceptor stimulation: milrinone as an alternative to dobutamine in the treatment of severe heart failure.
Mager G; Klocke RK; Kux A; Höpp HW; Hilger HH
Am Heart J; 1991 Jun; 121(6 Pt 2):1974-83. PubMed ID: 1852090
[TBL] [Abstract][Full Text] [Related]
10. Exploratory study of the effects of single doses of isomazole on hemodynamics and heart rate variability parameters in chronic heart failure.
Tuininga YS; van Veldhuisen DJ; Crijns HJ; van den Broek SA; Brouwer J; Haaksma J; Man in 't Veld AJ; Lie KI
J Cardiovasc Pharmacol; 1995 Jan; 25(1):81-6. PubMed ID: 7723357
[TBL] [Abstract][Full Text] [Related]
11. Saterinone: A New Dual-Action Drug in the Acute Management of Chronic Heart Failure.
Sridhara BS; Senior R; Anagnostou E; de La Motte S; Harrison FJ; Raftery EB; Lahiri A
Am J Ther; 1996 Aug; 3(8):597-601. PubMed ID: 11862296
[TBL] [Abstract][Full Text] [Related]
12. Contrasting preload-dependent hemodynamic and neurohumoral effects of isomazole, a partial phosphodiesterase inhibitor and calcium sensitizer.
Van der Ent M; Remme WJ; Bartels GL; De Leeuw PW; Van Hoogenhuyze DC; Kruijssen DA
J Card Fail; 1997 Dec; 3(4):277-86. PubMed ID: 9547442
[TBL] [Abstract][Full Text] [Related]
13. Hemodynamic and neurohumoral effects of long-term prostaglandin E1 infusions in outpatients with severe congestive heart failure.
Hülsmann M; Stanek B; Frey B; Berger R; Rödler S; Siegel A; Hartter E; Schuller M; Ogris E; Pacher R
J Heart Lung Transplant; 1997 May; 16(5):556-62. PubMed ID: 9171275
[TBL] [Abstract][Full Text] [Related]
14. Neurohumoral response to carmoxirole, a selective dopamine (D2) receptor agonist, in patients with chronic moderate heart failure.
van der Ent M; van den Heuvel AF; Remme WJ
Cardiovasc Drugs Ther; 1998 Sep; 12(4):387-94. PubMed ID: 9825185
[TBL] [Abstract][Full Text] [Related]
15. Selective inhibition of cAMP phosphodiesterase III activity by the cardiotonic agent saterinone in guinea pig myocardium.
Brunkhorst D; von der Leyen H; Meyer W; Schmidt-Schumacher C; Scholz H
Arzneimittelforschung; 1988 Sep; 38(9):1293-8. PubMed ID: 2852013
[TBL] [Abstract][Full Text] [Related]
16. Hemodynamic and neurohumoral effects of selective endothelin A (ET(A)) receptor blockade in chronic heart failure: the Heart Failure ET(A) Receptor Blockade Trial (HEAT).
Lüscher TF; Enseleit F; Pacher R; Mitrovic V; Schulze MR; Willenbrock R; Dietz R; Rousson V; Hürlimann D; Philipp S; Notter T; Noll G; Ruschitzka F;
Circulation; 2002 Nov; 106(21):2666-72. PubMed ID: 12438291
[TBL] [Abstract][Full Text] [Related]
17. Modulation of venous tone in heart failure.
Muir AL; Nolan J
Am Heart J; 1991 Jun; 121(6 Pt 2):1948-50. PubMed ID: 2035425
[TBL] [Abstract][Full Text] [Related]
18. Pharmacological properties of the positive inotropic and alpha 1-adrenoceptor blocking agent saterinone.
Armah BI; Hofferber E; Stenzel W
Arzneimittelforschung; 1988 Sep; 38(9):1287-92. PubMed ID: 2906245
[TBL] [Abstract][Full Text] [Related]
19. Hemodynamic, neurohumoral, and myocardial energetic effects of pimobendan, a novel calcium-sensitizing compound, in patients with mild to moderate heart failure.
Remme WJ; Kruijssen DA; van Hoogenhuyze DC; Krauss XH; Bartels GL; Storm CJ; de Leeuw PW
J Cardiovasc Pharmacol; 1994 Nov; 24(5):730-9. PubMed ID: 7532750
[TBL] [Abstract][Full Text] [Related]
20. Lack of stereoselectivity in the inotropic and phosphodiesterase inhibitory effects of saterinone enantiomers.
Armah BI; Muster D; Raap A; Brückner R; Graziadei I
Arzneimittelforschung; 1989 Nov; 39(11):1384-92. PubMed ID: 2559738
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
